循环肿瘤DNA中PIK3CA突变状态可预测Buparlisib联用氟维司群在部分应用芳香化酶抑制剂乳腺癌患者的疗效

PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib(BUP) Plus Fulvestrant(FULV)in Breast Cancer Patient with Aromatase Inhibitors

1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA（ct DNA）predicts efficacy of Buparlisib（BUP）plus Fulvestrant（FULV）in postmenopausal women with endocrine-resistant HR＋/HER2–advanced breast cancer（BC）：First results from the randomized,phaseⅢBELLE-2trial[C].San Antonio Breast Cancer Symposium,2015,abst S6-01.